Identification

Name
Nitrazepam
Accession Number
DB01595
Type
Small Molecule
Groups
Approved
Description

A benzodiazepine derivative used as an anticonvulsant and hypnotic.

Structure
Thumb
Synonyms
  • 1,3-dihydro-7-Nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
  • 2,3-dihydro-7-Nitro-5-phenyl-1H-1,4-benzodiazepin-2-one
  • 7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one
  • 7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
  • Apodorm
  • Atempol
  • Benzalin
  • Calsmin
  • Eatan
  • Eunoctin
  • Gerson
  • Hipnax
  • Hipsal
  • Ibrovek
  • Imeson
  • Imesont
  • N-Desmethylnimetazepam
  • Nelbon
  • Nelmat
  • Neozepam
  • Neuchlonic
  • Nitrazepamum
  • Paxisyn
  • Pelson
  • Persopit
  • Radedorm
  • Relact
  • Somitran
  • Sonebon
  • Sonnolin
  • Trazenin
External IDs
N05CD02 / NSC-58775 / RO 4-5360 / RO 5-3059
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MogadonTablet10 mgOralAa Pharma Inc1980-12-31Not applicableCanada
MogadonTablet5 mgOralAa Pharma Inc1980-12-31Not applicableCanada
NitrazadonTablet5 mgOralAa Pharma Inc1996-11-082014-06-25Canada
NitrazadonTablet10 mgOralAa Pharma Inc1996-11-082014-06-25Canada
Nitrazepam-10Tablet10 mgOralPro Doc Limitee2004-07-292010-07-13Canada
Nitrazepam-5Tablet5 mgOralPro Doc Limitee2004-07-292010-07-13Canada
Sandoz NitrazepamTablet10 mgOralSandoz Canada Incorporated1997-12-02Not applicableCanada
Sandoz NitrazepamTablet5 mgOralSandoz Canada Incorporated1997-12-02Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nitrazepam Tablets BPTablet5 mgOralApotex Corporation2002-09-17Not applicableCanada
Apo-nitrazepam Tablets BPTablet10 mgOralApotex Corporation2002-09-17Not applicableCanada
International/Other Brands
Alodorm / Arem / Benzalin / Insoma / Mogadon / Nitrados / Nitrosun / Ormodon / Pacisyn / Paxadorm / Remnos / Somnite / Surem / Unisomnia
Categories
UNII
9CLV70W7HS
CAS number
146-22-5
Weight
Average: 281.2661
Monoisotopic: 281.080041233
Chemical Formula
C15H11N3O3
InChI Key
KJONHKAYOJNZEC-UHFFFAOYSA-N
InChI
InChI=1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)
IUPAC Name
7-nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2)C=C1

Pharmacology

Indication

Used to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.

Associated Conditions
Pharmacodynamics

Nitrazepam is a type of benzodiazepine drug. It is a powerful hypnotic drug which possesses strong sedative, anxiolytic, amnestic, anticonvulsant, and skeletal muscle relaxant properties. Nitrazepam shortens the time required to fall asleep and lengthens the duration of sleep. It is also useful for the management of myoclonic seizures.

Mechanism of action

Nitrazepam belongs to a group of medicines called benzodiazepines. It acts on benzodiazepine receptors in the brain which are associated with the GABA receptors causing an enhanced binding of GABA (gamma amino butyric acid) to GABAA receptors. GABA is a major inhibitory neurotransmitter in the brain, involved in inducing sleepiness, muscular relaxation and control of anxiety and fits, and slows down the central nervous system. The anticonvulsant properties of nitrazepam and other benzodiazepines may be in part or entirely due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit delta
potentiator
Human
AGamma-aminobutyric acid receptor subunit epsilon
potentiator
Human
AGamma-aminobutyric acid receptor subunit pi
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit theta
potentiator
Human
USodium channel protein type 1 subunit alpha
other/unknown
Human
Absorption

Bioavailability is 53-94% following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

15-38 hours (mean elimination half life 26 hours).

Clearance
Not Available
Toxicity

Nitrazepam is a drug which is very frequently involved in drug intoxication, including overdose. Nitrazepam overdose may result in stereotypical symptoms of benzodiazepine overdose including intoxication, impaired balance, slurred speech. In cases of severe overdose this may progress to a comatose state with the possibility of death.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Aceprometazine.Approved
Acetyl sulfisoxazoleThe metabolism of Nitrazepam can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nitrazepam.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Nitrazepam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nitrazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AminophyllineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Nitrazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Nitrazepam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amperozide.Experimental
ApalutamideThe serum concentration of Nitrazepam can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Nitrazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrazepam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Asenapine.Approved
AtazanavirThe metabolism of Nitrazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Nitrazepam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Azaperone.Investigational, Vet Approved
AzelastineNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Benzyl alcohol.Approved
BoceprevirThe metabolism of Nitrazepam can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Nitrazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nitrazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nitrazepam.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrazepam.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Nitrazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Bupivacaine.Approved, Investigational
BuprenorphineNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nitrazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nitrazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nitrazepam.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Nitrazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Nitrazepam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Nitrazepam.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrazepam.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Citalopram.Approved
ClarithromycinThe metabolism of Nitrazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nitrazepam can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Nitrazepam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Nitrazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clozapine.Approved
CobicistatThe metabolism of Nitrazepam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Nitrazepam.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nitrazepam.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nitrazepam.Approved, Investigational
CrizotinibThe metabolism of Nitrazepam can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Nitrazepam can be decreased when combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrazepam.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Nitrazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrazepam.Approved
DabrafenibThe serum concentration of Nitrazepam can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Nitrazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Nitrazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Nitrazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nitrazepam can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrazepam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Nitrazepam is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Nitrazepam.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Nitrazepam.Approved, Illicit
DihydroergotamineThe metabolism of Nitrazepam can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Nitrazepam can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Nitrazepam.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Nitrazepam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Doxepin.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Nitrazepam.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nitrazepam.Approved, Investigational
DoxycyclineThe metabolism of Nitrazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Nitrazepam is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved, Illicit
DronedaroneThe metabolism of Nitrazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nitrazepam.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Nitrazepam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Nitrazepam can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Nitrazepam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nitrazepam.Approved, Investigational
EthanolNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nitrazepam.Approved
EzogabineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nitrazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Nitrazepam can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Nitrazepam.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nitrazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Nitrazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Nitrazepam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nitrazepam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nitrazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nitrazepam.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Nitrazepam can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Nitrazepam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Nitrazepam.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Nitrazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
IdelalisibThe metabolism of Nitrazepam can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Nitrazepam can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Nitrazepam can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Indiplon.Investigational
IsavuconazoleThe serum concentration of Nitrazepam can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Nitrazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Nitrazepam can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrazepam.Approved, Vet Approved
IsradipineThe metabolism of Nitrazepam can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Nitrazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nitrazepam can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nitrazepam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Nitrazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lamotrigine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nitrazepam.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Nitrazepam.Approved
LidocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Nitrazepam can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Nitrazepam can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Nitrazepam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Nitrazepam can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Nitrazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nitrazepam.Approved
LuliconazoleThe serum concentration of Nitrazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Nitrazepam can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lurasidone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Nitrazepam can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrazepam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Metaxalone.Approved
MethadoneNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Nitrazepam.Approved
MethotrimeprazineNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methylphenobarbital.Approved
MetyrosineNitrazepam may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Mianserin.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Nitrazepam.Approved, Illicit
MifepristoneThe serum concentration of Nitrazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved, Investigational
MirtazapineNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Nitrazepam can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nitrazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Nitrazepam.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nitrazepam.Approved
NefazodoneThe metabolism of Nitrazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nitrazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Nitrazepam can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Nitrazepam can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Nitrazepam can be decreased when combined with Nilotinib.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Nitrazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Nitrazepam can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Nitrazepam can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nitrazepam.Approved
OxprenololThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Nitrazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nitrazepam.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Nitrazepam can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Nitrazepam.Approved
ParaldehydeNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nitrazepam.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrazepam.Approved, Vet Approved
PentobarbitalThe metabolism of Nitrazepam can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nitrazepam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nitrazepam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Nitrazepam can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nitrazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Nitrazepam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Nitrazepam can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Nitrazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleNitrazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Nitrazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Nitrazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nitrazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nitrazepam.Approved
PSD502The risk or severity of adverse effects can be increased when Nitrazepam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Nitrazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitrazepam.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nitrazepam.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitrazepam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Nitrazepam.Approved, Investigational
RifabutinThe metabolism of Nitrazepam can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Nitrazepam can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Nitrazepam can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nitrazepam.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Nitrazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Romifidine.Vet Approved
RopiniroleNitrazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ropivacaine.Approved
RotigotineNitrazepam may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Nitrazepam can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nitrazepam.Approved
SaquinavirThe metabolism of Nitrazepam can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nitrazepam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitrazepam.Approved, Vet Approved
SildenafilThe metabolism of Nitrazepam can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nitrazepam.Approved
SiltuximabThe serum concentration of Nitrazepam can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Nitrazepam can be increased when it is combined with Simeprevir.Approved
Sodium oxybateNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
St. John's WortThe serum concentration of Nitrazepam can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Nitrazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam.Approved, Investigational
SulfisoxazoleThe metabolism of Nitrazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sultopride.Experimental
SuvorexantNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tasimelteon.Approved, Investigational
TeduglutideThe serum concentration of Nitrazepam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Nitrazepam can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Nitrazepam can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Nitrazepam.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetracaine.Approved, Vet Approved
TetracosactideTetracosactide may increase the hepatotoxic activities of Nitrazepam.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrodotoxin.Investigational
ThalidomideNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Nitrazepam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Nitrazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Nitrazepam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nitrazepam.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Nitrazepam.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Nitrazepam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrazepam.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Nitrazepam can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Nitrazepam can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Veralipride.Experimental
VerapamilThe metabolism of Nitrazepam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vigabatrin.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Nitrazepam.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Nitrazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Nitrazepam can be decreased when used in combination with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nitrazepam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Nitrazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zolazepam.Vet Approved
ZolpidemNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Nitrazepam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

References

General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820]
  2. Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. [PubMed:7782744]
  3. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451]
  4. Podhorna J, Krsiak M: Behavioural effects of a benzodiazepine receptor partial agonist, Ro 19-8022, in the social conflict test in mice. Behav Pharmacol. 2000 Apr;11(2):143-51. [PubMed:10877119]
  5. Nowakowska E, Chodera A: Studies on the involvement of opioid mechanism in the locomotor effects of benzodiazepines in rats. Pharmacol Biochem Behav. 1991 Feb;38(2):265-6. [PubMed:1676167]
External Links
Human Metabolome Database
HMDB0015534
KEGG Drug
D00531
KEGG Compound
C07487
PubChem Compound
4506
PubChem Substance
46505806
ChemSpider
4350
BindingDB
50020856
ChEBI
7581
ChEMBL
CHEMBL13209
Therapeutic Targets Database
DAP000691
PharmGKB
PA10242
Wikipedia
Nitrazepam
ATC Codes
N05CD02 — Nitrazepam
AHFS Codes
  • 28:24.08 — Benzodiazepines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentEpilepsies / Infantile Spasms (IS)1
3CompletedTreatmentSleep Initiation and Maintenance Disorders1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4RecruitingTreatmentEpilepsies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Mogadon 10 mg Tablet0.24USD tablet
Mogadon 5 mg Tablet0.16USD tablet
Apo-Nitrazepam 10 mg Tablet0.13USD tablet
Nitrazadon 10 mg Tablet0.11USD tablet
Sandoz Nitrazepam 10 mg Tablet0.11USD tablet
Apo-Nitrazepam 5 mg Tablet0.09USD tablet
Nitrazadon 5 mg Tablet0.08USD tablet
Sandoz Nitrazepam 5 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)225 °CPhysProp
logP2.25HANSCH,C ET AL. (1995)
logS-3.8ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0299 mg/mLALOGPS
logP1.95ALOGPS
logP2.55ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)11.9ChemAxon
pKa (Strongest Basic)2.61ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area87.28 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity79.22 m3·mol-1ChemAxon
Polarizability27.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.9802
Caco-2 permeable+0.5176
P-glycoprotein substrateSubstrate0.5785
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9205
Renal organic cation transporterNon-inhibitor0.8307
CYP450 2C9 substrateNon-substrate0.7695
CYP450 2D6 substrateNon-substrate0.8583
CYP450 3A4 substrateSubstrate0.6725
CYP450 1A2 substrateInhibitor0.7569
CYP450 2C9 inhibitorNon-inhibitor0.6133
CYP450 2D6 inhibitorNon-inhibitor0.8986
CYP450 2C19 inhibitorInhibitor0.5682
CYP450 3A4 inhibitorInhibitor0.6791
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5645
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7197
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9904
hERG inhibition (predictor II)Non-inhibitor0.8498
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0zgi-2490000000-84b5bf7df62c745f8414
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0090000000-8f7713c4e618326c1d9b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0090000000-d514d232dff7c473d32f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0090000000-e2a1a64f13da7ed85586
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0uk9-0190000000-f22bb948e3a20dfd2bff
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-006x-0980000000-f78bdd1a7e391dbaad48
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0920000000-d334a1a23130e08b3d55
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-1900000000-3808670d5ccc91bd0e38
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0uxu-3900000000-1fc08ceb9c88d5c734ca
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-5900000000-cbcd46c7ea13a9ff18cb
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00lr-0090000000-bc49e652f5e2e4f4b760
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0090000000-c63c1250878b61e6d0da
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0090000000-02d4e0b73c57e157d6b0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0019-0090000000-6623ad5dc09e01b5a573
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0390000000-38d5874ebcc0e05f411c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-053r-0970000000-ce2d7caefc3860d70fa4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-053r-0930000000-670ac85a651f0faf0d7d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-1900000000-f96a507afa68e1b3a438
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-2900000000-c9082e2a3a5a56cfe408
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-3900000000-310a824d6452fa47d987
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0190000000-6d4a0096179c1ef67c5a
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives / Nitroaromatic compounds / Benzene and substituted derivatives / Secondary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
1,4-benzodiazepine / Alpha-amino acid or derivatives / Nitroaromatic compound / Monocyclic benzene moiety / Benzenoid / Carboxamide group / Ketimine / Lactam / C-nitro compound / Organic nitro compound
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
C-nitro compound, 1,4-benzodiazepinone (CHEBI:7581)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
  3. Podhorna J, Krsiak M: Behavioural effects of a benzodiazepine receptor partial agonist, Ro 19-8022, in the social conflict test in mice. Behav Pharmacol. 2000 Apr;11(2):143-51. [PubMed:10877119]
  4. Tanaka M, Suemaru K, Watanabe S, Cui R, Li B, Araki H: Comparison of short- and long-acting benzodiazepine-receptor agonists with different receptor selectivity on motor coordination and muscle relaxation following thiopental-induced anesthesia in mice. J Pharmacol Sci. 2008 Jul;107(3):277-84. Epub 2008 Jul 5. [PubMed:18603831]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB1
Uniprot ID
P18505
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-1
Molecular Weight
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-gated chloride ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB3
Uniprot ID
P28472
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-3
Molecular Weight
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG1
Uniprot ID
Q8N1C3
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-1
Molecular Weight
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG3
Uniprot ID
Q99928
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-3
Molecular Weight
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRD
Uniprot ID
O14764
Uniprot Name
Gamma-aminobutyric acid receptor subunit delta
Molecular Weight
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRE
Uniprot ID
P78334
Uniprot Name
Gamma-aminobutyric acid receptor subunit epsilon
Molecular Weight
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
Gene Name
GABRP
Uniprot ID
O00591
Uniprot Name
Gamma-aminobutyric acid receptor subunit pi
Molecular Weight
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
Gene Name
GABRR1
Uniprot ID
P24046
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-1
Molecular Weight
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
Gene Name
GABRR2
Uniprot ID
P28476
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-2
Molecular Weight
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRR3
Uniprot ID
A8MPY1
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-3
Molecular Weight
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transmembrane signaling receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRQ
Uniprot ID
Q9UN88
Uniprot Name
Gamma-aminobutyric acid receptor subunit theta
Molecular Weight
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN1A
Uniprot ID
P35498
Uniprot Name
Sodium channel protein type 1 subunit alpha
Molecular Weight
228969.49 Da
References
  1. McLean MJ, Macdonald RL: Benzodiazepines, but not beta carbolines, limit high frequency repetitive firing of action potentials of spinal cord neurons in cell culture. J Pharmacol Exp Ther. 1988 Feb;244(2):789-95. [PubMed:2450203]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Tassaneeyakul W, Birkett DJ, Miners JO: Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 1998 Mar;28(3):293-301. [PubMed:9574817]

Drug created on August 29, 2007 11:49 / Updated on June 24, 2018 11:36